<DOC>
	<DOCNO>NCT02095782</DOCNO>
	<brief_summary>This single arm phase II clinical trial , aim evaluate effectiveness intercalate combination doublet chemotherapy paclitaxel plus carboplatin erlotinib patient advanced stage non-small-cell lung cancer low abundant activate EGFR mutation .</brief_summary>
	<brief_title>Chemotherapy Erlotinib Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation</brief_title>
	<detailed_description>Primary therapy stage : Paclitaxel Patients receive six cycle Paclitaxel ( 175 mg/m² day 1 4 week cycle , intravenously ) plus carboplatin ( AUC=5 , intravenously day 1 4 week cycle , intravenously ) sequential erlotinib ( 150 mg/day ) day 8-21 cycle . Maintenance therapy stage : Patients , complete 6 cycle therapy without progression intolerable toxicity , receive erlotinib ( 150 mg/day ) maintenance therapy progression , intolerable toxicity death .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients histologically document , locally advanced recurrent ( stage IIIb amenable combined modality treatment ) metastatic ( stage IV ) nonsmall cell lung cancer . Low abundant activate EGFR mutation : EGFR exon 19 deletion exon 21 L858R , positive realtime PCR method negative standard sequence method . Uncommon EGFR mutation include exclude exon 20 mutation . ECOG performance status ≤ 2 . Patients administer first line set platinum base chemotherapy . Patients must measurable disease accord RECIST ( version 1.1 ) criterion . Life expectancy least 12 week . Age ≥ 18 year . Written ( sign ) inform Consent participate study . Adequate organ function define follow criterion : Liver function : SGOT ( AST ) SGPT ( ALT ) ≤ 2.5 X ULN absence liver metastases 5 X ULN case liver metastasis . Total bilirubin ≤ 1.5ULN . Bone marrow function : Granulocyte count ≥ 1,500/mm3 platelet count ≥100,000/mm3 hemoglobin ≥90g/dl . Renal function : serum creatinine ≤ 1.5 ULN creatinine clearance ≥ 60 ml/min . ( base modify CockcroftGault formula ) . For female childbearing potential negative serum/urine pregnancy test must obtain within 48 hour enrollment . Postmenopausal woman must amenorrhoeic least 12 month consider nonchildbearing potential . Patients prior chemotherapy systemic anticancer therapy include target therapy target HER family member ( erlotinib , gefitinib , cetuximab , trastuzumab , etc ) . Previous adjuvant neoadjuvant treatment nonmetastatic disease permit complete ≥ 6 month enrollment . Patients history malignancy within 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer ) . Patients brain metastasis spinal cord compression . It permit patient treat surgery and/or radiation evidence stable disease least 4 week . Patients risk ( investigator 's opinion ) transmit human immunodeficiency virus ( HIV ) blood body fluid . Nursing lactate woman . Sexually active male female ( childbearing potential ) unwilling practice contraception study . Unwilling write inform consent participate study . Patients unwilling accept followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>erlotinib</keyword>
	<keyword>chemotherapy</keyword>
</DOC>